Submission of Annual Report for the FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals Ltd (BSE Scrip Code: 524711) has filed its 34th Annual Report for FY 2024-25 along with the notice for its 34th Annual General Meeting (AGM) to be held on Tuesday, September 30, 2025 at 11:00 AM through video conferencing. The AGM will cover routine items like adoption of the FY25 audited financial statements, re-appointment of two directors who are retiring by rotation, and re-appointment of statutory auditors M/s A.M Reddy & D.R. Reddy for a second 5-year term (till FY 2029-30) at a proposed audit fee of Rs. 2 lakh for FY25. The company is also seeking shareholder approval to appoint M/s Aakanksha Dubey & Co as new Secretarial Auditors for 5 years, and to re-appoint Managing Director Mr. Murali Meraga and two Whole-Time Directors (Mr. Pavan Sathvik Gilaka and Dr. Dhananjaya Alli) for 3-year terms each. Notably, all three executive directors are being re-appointed without any remuneration. E-voting is being managed by CDSL, with September 23, 2025 as the cut-off date for voting eligibility.
This is a routine annual filing and AGM notice with no major surprises. The re-appointment of all three executive directors without remuneration is unusual and may suggest these directors have alternative income or aligned interests. Shareholders should review the full Annual Report for FY25 financials before casting votes on the September 30, 2025 AGM resolutions.